Details about Adrian Towse
Access statistics for papers by Adrian Towse.
Last updated 2024-10-10. Update your information in the RePEc Author Service.
Short-id: pto443
Jump to Journal Articles
Working Papers
2022
- Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases
Post-Print, HAL
See also Journal Article Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases, Applied Economics Letters, Taylor & Francis Journals (2023)  (2023)
- An Ambitious USG Advanced Commitment for Subscription-Based Purchasing of Novel Antimicrobials and Its Expected Return on Investment
Policy Papers, Center for Global Development View citations (1)
2020
- How Should the World Pay for a COVID-19 Vaccine?
Monograph, Office of Health Economics View citations (2)
2019
- Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?
Briefing, Office of Health Economics
- Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?
Briefing, Office of Health Economics
- The Future of Global Health Procurement: Issues around Pricing Transparency
Working Papers, Center for Global Development View citations (2)
2018
- Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
Briefing, Office of Health Economics View citations (4)
2017
- Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?
Briefing, Office of Health Economics
- Incentives for New Drugs to Tackle Anti-Microbial Resistance
Briefing, Office of Health Economics View citations (2)
2016
- How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?
Briefing, Office of Health Economics
2015
- Multi-indication Pricing: Pros, Cons and Applicability to the UK
Seminar Briefing, Office of Health Economics View citations (6)
2014
- Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?
Occasional Paper, Office of Health Economics
2013
- Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold
Occasional Paper, Office of Health Economics View citations (12)
2012
- The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?
Occasional Paper, Office of Health Economics View citations (3)
- Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context
NBER Working Papers, National Bureau of Economic Research, Inc View citations (6)
See also Journal Article Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context, Health Economics, John Wiley & Sons, Ltd. (2015) View citations (12) (2015)
2011
- Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement
NBER Working Papers, National Bureau of Economic Research, Inc View citations (6)
See also Journal Article Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement, Health Economics, John Wiley & Sons, Ltd. (2015) View citations (12) (2015)
- Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
Occasional Paper, Office of Health Economics View citations (2)
2010
- New Drugs to Tackle Antimicrobial Resistance: EU Policy Options
Occasional Paper, Office of Health Economics View citations (1)
2008
- The Market for Biosimilars: Evolution and Policy Options
Briefing, Office of Health Economics View citations (9)
2006
- Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds
Briefing, Office of Health Economics
2003
- Reducing Harm to Patients in the National Health Service. Will the Government’s Compensation Proposals Help?
Briefing, Office of Health Economics View citations (1)
1998
- From Efficacy to Cost-Effectiveness
Briefing, Office of Health Economics View citations (3)
1997
- Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry
Briefing, Office of Health Economics View citations (2)
Journal Articles
2023
- Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases
Applied Economics Letters, 2023, 30, (16), 2195-2199
See also Working Paper Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases, Post-Print (2022) (2022)
2022
- Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy
Applied Health Economics and Health Policy, 2022, 20, (5), 651-667 View citations (1)
2021
- Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al
Medical Decision Making, 2021, 41, (3), 255-257 View citations (1)
2019
- Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare
The European Journal of Health Economics, 2019, 20, (3), 427-438 View citations (12)
- Is rate of return pricing a useful approach when value-based pricing is not appropriate?
The European Journal of Health Economics, 2019, 20, (7), 945-948 View citations (2)
2017
- Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation
Health Policy, 2017, 121, (10), 1025-1030 View citations (8)
2016
- Biosimilars: How Can Payers Get Long-Term Savings?
PharmacoEconomics, 2016, 34, (6), 609-616 View citations (9)
- Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria
Oxford Review of Economic Policy, 2016, 32, (1), 64-87
2015
- European Union Pharmaceutical Markets: A Case for Differential Pricing?
International Journal of the Economics of Business, 2015, 22, (2), 263-275 View citations (9)
- Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement
Health Economics, 2015, 24, (2), 238-252 View citations (12)
See also Working Paper Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement, NBER Working Papers (2011) View citations (6) (2011)
- Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context
Health Economics, 2015, 24, (3), 294-301 View citations (12)
See also Working Paper Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context, NBER Working Papers (2012) View citations (6) (2012)
2014
- Orphan drugs policies: a suitable case for treatment
The European Journal of Health Economics, 2014, 15, (4), 335-340 View citations (10)
2013
- Operationalizing Value-Based Pricing of Medicines
PharmacoEconomics, 2013, 31, (1), 1-10 View citations (15)
2012
- Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?
The European Journal of Health Economics, 2012, 13, (1), 1-5 View citations (16)
2011
- Incentives for R&D for New Antimicrobial Drugs
International Journal of the Economics of Business, 2011, 18, (2), 331-350 View citations (1)
2007
- If it ain't broke, don't price fix it: the OFT and the PPRS
Health Economics, 2007, 16, (7), 653-665 View citations (8)
2006
- The desirability and feasibility of economic studies of drugs post-launch
The European Journal of Health Economics, 2006, 7, (1), 5-6 View citations (1)
2004
- Genetic screening, health care and the insurance industry
The European Journal of Health Economics, 2004, 5, (2), 116-121 View citations (3)
1999
- Is disease management relevant in Europe: some evidence from the United Kingdom
Health Policy, 1999, 48, (1), 69-77
- Medical negligence and the NHS: an economic analysis
Health Economics, 1999, 8, (2), 93-101 View citations (8)
1994
- The Political Economy of Healthcare. By David Resisman. MacMillan Press, London, 1993. No. of pages: 267. ISBN: 0‐333‐58579‐8
Health Economics, 1994, 3, (5), 347-348
|
The links between different versions of a paper are constructed automatically by matching on the titles.
Please contact if a link is incorrect.
Use this form
to add links between versions where the titles do not match.
|
EconPapers is hosted by the
School of Business at Örebro University.